Physician profile
Douglas Reznick
NPI 1124002456
$293,650.49
in general payments reported to CMS, 2019-2025
22 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132K · 2020: $61K · 2021: $36K · 2022: $19K · 2023: $8,609 · 2024: $8,825 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $13K · Food and Beverage: $1,835 · Travel and Lodging: $1,308 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,010.00 |
| Consulting Fee | $12,575.00 |
| Food and Beverage | $1,835.17 |
| Travel and Lodging | $1,308.44 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $258,648.04 | 2019-2025 | Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $15,289.73 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $8,353.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $7,396.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,625.00 | 2024 | Alunbrig |
| Astrazeneca Uk Limited | $1,387.50 | 2021 | |
| Ethicon INC. | $267.58 | 2021-2025 | Monarch Platform |
| Tactile Systems Technology INC | $168.42 | 2024 | Flexitouch Plus, Entre Plus |
| Monteris Medical Corporation | $136.44 | 2025 | Neuroblate |
| Amgen INC. | $63.17 | 2021-2022 | |
| Celgene Corporation | $43.27 | 2024-2025 | Reblozyl |
| Tolmar, INC. | $40.57 | 2024-2025 | Eligard, Rubraca |
| Exelixis INC. | $39.52 | 2023 | Cabometyx |
| Astellas Pharma US INC | $34.97 | 2024 | Vyloy |
| Eisai INC. | $27.02 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $22.27 | 2025 | Jakafi |
| Pharmaand Gmbh | $21.06 | 2025 | Rubraca |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Abbvie INC. | $19.59 | 2024 | |
| Pfizer INC. | $17.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.93 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Reznick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.